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Abstract 
Here we describe methods for the production of adeno-associated viral (AAV) 
vectors by transient transfection of HEK293 cells grown in serum-free medium 
in orbital shaken bioreactors and the subsequent purification of vector 
particles. The protocol for expression of AAV components is based on 
polyethyleneimine (PEI) mediated transfection of a 2-plasmid system and is 
specified for production in milliliter- to liter-scales. After PEI and plasmid DNA 
(pDNA) complex formation the diluted cell culture is transfected without a prior 
concentration step or medium exchange. Following a three-day batch 
process, cell cultures are further processed using different methods for lysis 
and recovery. Methods for the purification of viral particles are described, 
including iodixanol gradient purification, immunoaffinity chromatography and 
ultrafiltration, as well as quantitative PCR to quantify vector titer.  
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1. Introduction 
Adeno-associated viral (AAV) vectors are amongst the most popular viral 
vectors for gene therapy applications in pre-clinical and clinical research (1). 
Discovered in 1965, AAV are non-pathogenic members of the Dependovirus 
genus of the parvoviruses and are endemic in humans (2, 3). Besides the 
numerous clinical trials that have been conducted to date, the recent approval 
by the FDA of Luxturna™, an AAV-based gene therapy to treat an inherited 
condition leading to blindness (Spark Therapeutics), demonstrates the 
popularity and feasibility of AAV-based gene therapy approaches. For many 
years, optimizing transgene delivery and expression, and the cell or tissue 
specificity of AAV variants, has been the focus of translational research. It is 
now that this technology reaches the market when needs and challenges 
concerning manufacturing and quality become most apparent. As a 
consequence, the focus of research and development is shifting into process 
development. 
Today, one commonly used AAV production platform is based on plasmid 
transfection of adherent HEK293 cells grown in serum-containing media. This 
production method is difficult to scale-up, labor intensive and 
disadvantageous for manufacturing. Therefore cost-effective and scalable 
protocols are needed for large-scale AAV vector production. Recent research 
has validated the use of orbital shaking technology (OSR) for the cultivation of 
HEK293 cells in suspension, using disposable vessels up to a 1,000-Liter 
scale (4). Key features of the OSR technology are high gas transfer rates, low 
sheer stress for cells, low mixing times and low specific power consumption 
(5-7). These characteristics make the OSR technology one of the most 
promising disposable bioreactor platforms for animal cell culture for small- and 
large-scale operations. In parallel, different groups have demonstrated the 
technical feasibility to scale-up AAV production by transfecting suspension 
adapted HEK293 cells without prior concentration of cells or exchange of 
medium (8, 9). Here, we describe the transient transfection of suspension-
adapted HEK293 cells in orbital shaken bioreactors for the production of AAV 
vectors. 
 
Next to the upstream processing for vector manufacturing, scalable methods 
are also required for the downstream processing in order generate AAV 
vectors that satisfy the requirements for clinical application. In many labs, the 
purification via gradient centrifugation is commonly used for lab-scale isolation 
of AAV vectors harvested from cell pellets. This density-based method has 
the advantage that it allows the removal of empty AAV particles. 
Nevertheless, as this operation is very laborious to process larger liquid 
volumes, it would not be suitable at a scale relevant for studies in large animal 
models or for clinical trials. As an alternative to centrifugation, 
chromatographic purification procedures can be applied. Various methods 
have been described for AAV purification in the past including ion exchange 
chromatography, hydrophobic interaction chromatography, and size exclusion 
chromatography (10-13). These have been applied successfully to achieve 
high purity, but often suffer from low recovery rates. The recent development 
of affinity ligands and resins offers a solution to this issue. Thanks to their high 
selectivity, affinity ligands allow the efficient removal of impurities while 
maximizing vector recovery (14, 15). The possibility to scale-up and to 
process large liquid volumes makes affinity chromatography an ideal option 
for downstream processing of AAV vectors at all scales.  
 
2. Materials 
2.1 Cell culture 
1. HEK293 cells (ExcellGene SA, Monthey, Switzerland) adapted to serum-
free medium and cultivated in orbital shaken bioreactors.  
2. TubeSpin 50 bioreactor and TubeSpin 600 bioreactor tubes (TPP, 
Trasadingen, Switzerland) (see Note 1)  
3. Serum-free Freestyle F17 Expression medium (Thermo Fisher Scientific 
AG, Reinach, Switzerland) (F17) is supplemented with L-alanyl-L-glutamine 
(Gibco Glutamax, Thermo Fisher Scientific) by adding 20 mL of a 200 mM 
stock solution to 1 L of F17 medium. Additionally Pluronic F-68 (Thermo 
Fisher Scientific) was added to a final concentration of 0.1 % (10 mL of a 10% 
stock solution in 1 L F17 medium). 
4. 0.4 % Trypan Blue solution  
5. Phosphate-buffered saline (PBS).  
6. ISF1-X or ISF4-X incubator shaker (Adolf Kühner AG, Birsfelden, 
Switzerland) 
7. Phase contrast microscope 
 
2.2 Transfection 
1. Linear 25 kDa polyethyleneimine (PEI) (Polysciences, Eppenheim, 
Germany): to prepare the 1 mg/mL PEI stock solution, 1 g of PEI is weighed 
and transferred in 800 mL water. To dissolve the PEI, the pH is lowered to 
about 3 by adding 1 N HCl. Once PEI is dissolved, the pH is increased to 7.0 
with 1 N NaOH and the volume adjusted to 1 L with water. Next, the solution 
is sterile-filtered using a bottle-top filter (0.2 µm) and aliquoted into sterile 50-
mL tubes for storage at −20°C. 
2. Shuttle plasmid containing the sequence encoding the gene of interest 
flanked by two ITRs, typically derived from AAV serotype 2 (see Note 2). 
3. pDP-helper plasmid encoding the rep (AAV2) and cap genes (serotype 
dependent), and adenoviral helper genes (VA, E2A, E3, and E4) (see Note 3). 
4. Plasmid DNA (pDNA) obtained from contract manufacturer. Adjusted to 
concentrations of 1 mg/mL with distilled water for long-term storage (-80°C). 
 
2.3 Harvest and lysis 
1. Triton X-100 (Merck, Zug, Switzerland)  
2. 10x Lysis buffer: 1% Triton X-100, 20 mM MgCl2 in 500 mM Tris buffer pH 
7.4 
3. Dry ice 
4. 70% ethanol  
5. 5 M NaCl, sterile filtered  
6. Benzonase 25 kU/mL (Merck) 
7. 10% CHAPS (3-[(3-cholamidopropyl)dimethylammonio]-1-
propanesulfonate) (Axon Lab AG, Le Mont-sur-Lausanne, Switzerland)  
8. Supracap™ depth filter, 0.4 - 1.0 μm, Seitz BIO 20 media (Pall, Basel, 
Switzerland) 
9. AcroPak™ 0.8/0.45 µm membrane filter (Pall) 
10. Hermle Z 513 K centrifuge and Hermle 220.70 rotor with tube holder for 
TubeSpin 50 and Tubespin 600 (Hermle Labortechnik GmbH, Wehingen, 
Germany) (for cell harvest at 1,000xg) 
11. Sorvall Evolution RC centrifuge and Sorvall SLA-600TC Super-Lite rotor 
(50 mL centrifugal tubes) (Thermo Fisher Scientific) (for removal of cell debris 
at 10,000xg) 
 
2.4 Iodixanol gradient centrifugation 
1. Optiprep (Axon Lab AG, Baden-Dattwil, Switzerland), sterile and 
endotoxin tested multi-purpose medium based on 60% iodixanol in water. 
2. 0.5 % Phenol red solution  
3. PBS-MK buffer: DPBS (500 mL) supplemented with 50 mg MgCl2 × 6H2O. 
4. PBS-MK 1M NaCl: obtained by addition of 36 g NaCl to 1 L PBS-MK 
5. Preparation of 4 gradient solutions, 50 ml final volume: 
 15%: 12.5 ml Optiprep, 37.5 ml PBS-MK 1 M NaCl 
 25%: 20.8 ml Optiprep, 29.2 ml PBS-MK and 125 µL Phenol red 
 40%: 33 ml Optiprep and 17 ml PBS-MK  
 60%: 50 ml Optiprep and 125 µL Phenol red 
6. Beckman Coulter ultracentrifuge Optima 90-K (Beckman Coulter, Nyon, 
Switzerland)  
7. Rotor 70Ti (Beckman Coulter) 
8. OptiSeal polypropylene tubes (32.4 mL) (Beckman Coulter)  
9. Spacer (Adapter for tubes in Rotor 70Ti) (Beckman Coulter) 
10. Syringes 10 ml (B.Braun, Sempach, Switzerland) 
11. Needle 18 Gauge (Thermo Fisher Scientific) 
12. Syringe equipped with spinal needle (1.27 x 89 mm) (Becton Dickinson, 
Allschwil, Switzerland) 
 
2.5 Immunoaffinity chromatography 
1. POROS™ CaptureSelect™ AAV9, AAV8 and AAVX resin (Thermo Fisher 
Scientific) (see Note 4) 
2. Omnifit® column (Diba Industries Inc, Danbury, CT, USA) with movable end 
piece. 
3. Equilibration buffer: PBS, pH 7.4 
4. 0.1 M citric acid monohydrate solution 
5. 0.1 M trisodium citrate dehydrate solution 
6. 50 mM citrate elution buffer: citric acid buffer pH 3 is prepared by mixing 
82 mL of the 0.1 M citric acid monohydrate solution and 18 mL of the 0.1 M 
trisodium citrate dihydrate solution. The resulting solution is diluted two fold to 
obtain 50 mM citrate elution buffer (see Note 5) 
7. Regeneration buffer: 5 M guanidine hydrochloride  
8. Cleaning buffer: 0.1 M phosphoric acid  
9. ÄKTA Pure chromatography controller (GE Healthcare, Glattbrugg, 
Switzerland) 
10. Fraction collector F9-R (GE Healthcare) 
11. UNICORN 7 control software for ÄKTA purification systems (GE 
Healthcare) 
 
2.6 Ultrafiltration  
1. DPBS (without calcium and magnesium) (Thermo Fisher Scientific) 
2. DPBS (Thermo Fisher Scientific) 
3. Amicon® Ultra-15 centrifugal filter units, molecular weight cutoff (MWC) 100 
kDa (Merck) 
4. Amicon® Ultra-4 centrifugal filter units, MWC 100 kDa (Merck) 
 
2.7 Quantitative Polymerase chain reaction (qPCR) 
1. Rotor gene probe qPCR kit (Qiagen AG, Hombrechtikon, Switzerland) 
2. Forward primer (4 µM) (see Note 6) 
3. Reverse primer (4 µM) (see Note 6) 
4. qPCR probe (2 µM) (see Note 6) 
5. QuantStudio 6 Flex Real-Time PCR system (Thermo Fisher Scientific) 
 
Methods 
3.1 Cell culture  
1. Frozen HEK293 cells are thawed at 37°C and immediately transferred into 
a centrifuge tube containing 10 mL pre-warmed F17 medium.  
2. After quick shaking by hand the tube is centrifuged at 500xg for 3 min.  
3. The supernatant is discarded and cells are resuspended with pre-warmed 
10 mL F17 medium and transferred into a TubeSpin 50 bioreactor tube. 
Henceforth, the cultures are maintained at 37°C, 80% humidity, 5% CO2 and 
constant shaking at 180 rpm (shaking diameter 5 cm). (see Note 7)  
4. After 3-4 days cells are counted using the Trypan blue staining, a Neubauer 
hemocytometer and an inverted phase contrast microscope. (see Note 8) 
5. Based on the viable cell density, the cell suspension is diluted to a final 
concentration of 1×106 cells/mL by transferring the according cell culture 
volume into fresh and pre-warmed F17 medium. (see Note 8)  
6. To maintain the cell culture at high viability, the cells are passaged twice 
per week.  
 
3.2 Transient transfection 
1. Three days before transfection, cells are seeded at 1×106 cells/mL in a 
volume corresponding to the desired scale of vector production (TubeSpin 50 
or TubeSpin 600 bioreactor tube). (see Note 9) 
2. On the day of transfection, cells are counted as previously described (see 
3.1) and diluted to 1×106 cells/mL in fresh F17 medium (TubeSpin 50 or 
TubeSpin 600 bioreactor tube). 
3. The helper and shuttle plasmids are pre-mixed at equimolar ratios, with the 
total amount of DNA and volume depending on the scale of transfection and 
the total cell number (Table 1). 
4. A volume of F17 medium (room temperature) corresponding to 5% of the 
cell culture is added to a sterile polystyrene tube (depending on scale of 
transfection use 5 mL or 19 mL tube). 
5. A total of 1.5 µg of pDNA per million cells is added to the F17 medium. The 
tube is then shaken briefly. (see Note 10) 
6. 3 µg of PEI per million cells is added to the tube (DNA:PEI = 1:2 [w/w]). 
(see Note 10) 
7. At this point the tube is gently vortexed. 
8. The tube is then incubated for 10 min at room temperature for pre-complex 
formation. (see Note 11) 
9. The whole content of the tube is then transferred to the cell suspension for 
transfection.  
10. The cell culture is subsequently incubated at standard conditions 
described above (3.1, step 3.) for 48-72 h before vector harvest (Figure 1). 
(see Note 12)  
 
 
 
 
 
 
 
Table 1: Parameters for transfections at different scales using TubeSpin 
bioreactors.  
 
 
Culture 
vessel 
Culture 
Volume [mL] 
Cell density 
Transfection Cells total 
Pre-mix 
volume [mL] DNA [µg] PEI [µg] 
TubeSpin 50 10 1x106 10x106 0.5 15 30 
TubeSpin 600 100 1x106 100x106 5 150 300 
TubeSpin 600 250 1x106 250x106 12.5 375 750 
 
 
3.3 Harvest 
If purification via gradient centrifugation is intended as a one-step purification, 
only the cells are processed to isolate intracellular AAV particles. For 
immunoaffinity chromatography, it is optional to collect cells and/or culture 
medium. As it is possible to process larger liquid volumes with this method, 
cells can also be lysed in the cell culture directly. (see below 3.4.2)  
1. The cells are harvested by centrifuging the TubeSpin 50 bioreactors at 
1,000xg for 5 min or TubeSpin 600 bioreactor tubes at 1,000xg for 10 
min. It is recommended to collect and store at -20°C a sample of the 
supernatant at this point to determine the amount of particles released 
by the packaging cells (e.g. by quantifying the amount of genome-
containing particles via qPCR).  
2. Discard the supernatant and gently resuspend the pellet in 10 mL PBS. 
3. Transfer in a 50 mL polypropylene centrifuge tube and centrifuge at 
1,000xg for 7 min. 
4. After discarding the remaining supernatant, the cell pellet is further 
processed, continuing with the steps described in 3.4.1 or 3.4.2. The 
cell pellet can be stored at -20°C before further processing.  
 
3.4 Lysis 
3.4.1 Freeze-thaw lysis (see Note 13) 
1. Mix dry ice with 70% ethanol. 
2. If required, thaw the pellet initially in a water bath at 37°C. 
3. Resuspend the pellet in PBS with a volume corresponding to 2% of the 
initial cell culture volume. 
4. Then freeze (10 min) in dry ice-ethanol mix and thaw (10 min) in 37°C 
water bath. After thawing, the suspension is vortexed vigorously for 30 sec. 
This procedure is repeated three times (Figure 1). 
5. Add Benzonase at 50 U/mL and incubate 30 min at 37°C under agitation 
(100 rpm). 
6. Add 0.5% CHAPS, incubate 30 min at 37°C and 100 rpm.  
7. Add 5 M sodium chloride to a final concentration of 0.1 M and vortex briefly. 
The volume can be estimated based on the graduation displayed on the 50 
mL polypropylene centrifuge tube. 
8. Centrifuge for 10 min at 10,000xg, 4°C. 
9. Pass the supernatant through a 0.45 µm filter (see Note 14). The lysate is 
ready for iodixanol gradient centrifugation or immunoaffinity chromatography. 
(see Note 15) 
 
3.4.2 Triton X-100 lysis  
1. Add 10% (v/v) lysis buffer to the cell culture (Figure 1). If only the cell pellet 
is processed, resuspend the pellet in PBS with a volume corresponding to 2% 
of the initial cell culture volume. (see Note 16) 
2. Add Benzonase at 50 U/mL. 
3. Incubate at 37°C, 100 rpm shaking for 30 min. 
4. Add 5 M sodium chloride to a final concentration of 0.1 M and briefly vortex. 
The volume can be estimated based on the graduation displayed on the 50 
mL centrifuge tube. 
5. If only the cell pellet is processed and the volume does not exceed 15 mL, 
centrifuge for 10 min at 10,000xg, 4°C (Figure 1). For larger volumes, proceed 
with step 6. 
6. Pass the lysate through a depth filter for clarification and removal of debris. 
7. Pass the supernatant through a 0.8 µm pre-filter and then through a 
0.45 µm filter. It is also possible to use filter capsules with a built-in pre-filter. 
(see Note 14)  
8. The lysate is ready for iodixanol gradient centrifugation or immunoaffinity 
chromatography. (see Note 15) 
 
3.5 Iodixanol gradient centrifugation 
1. Rinse ultracentrifuge tube with sterile PBS to remove electrostatic charge 
that may cause air bubbles otherwise.  
2. Place sterile OptiSeal tube, washed in PBS, in the assembly rack. 
3. Pipette the lysate (6 mL maximal volume) at the bottom of the 30 ml 
ultracentrifuge tube.  
4. Using a needle connected to a syringe, underlay the lysate with 15% (7 
mL), 25% (5 mL), 40% (5 mL) and 60% (8 mL) iodixanol solutions (Optiprep). 
This can be achieved by carefully placing the tip of the needle at the very 
bottom of the tube for each of the different solutions sequentially added 
according to increasing iodixanol concentrations.  
5. The tube is then sealed before centrifugation. 
6. Centrifuge in 70Ti rotor at 350,000xg for 1 h at 4°C. 
7. Fix the tube on holder, remove the rubber lid from top and insert syringe 
with 18G needle at the border between the 60% and the 40% iodixanol 
fractions, with the needle facing upwards to the lower portion of the 40% 
iodixanol fraction where the viral particles accumulate. 
8. Carefully remove the entire 40% iodixanol layer (transparent), without 
disturbing the layer of protein contaminants that accumulate at the interphase 
between the 40% and 25% iodixanol layers. It is typically possible to collect 4-
5 mL of suspension. 
9. Dilute 1:1 in PBS pH 7.4. 
10. Continue with the ultrafiltration described in 3.7. 
 3.6 Immunoaffinity chromatography 
This method has been implemented using the Poros™ CaptureSelect™ AAV9 
and AAV8 resins. The AAVX resin has recently been introduced. Together, 
these three commercially available resins allow the purification of capsids of 
the AAV1 through AAV9 serotypes, and possibly a variety of modified and 
chimeric serotypes. (see Note 17) 
 1. After gently mixing the bottle containing the resin (resins are supplied as 
approximately 56% slurry in 18% ethanol), the desired amount of slurry is 
transferred to an Omnifit® column with a serological pipette. 
2. After transferring the slurry, the resin is allowed to settle by gravity. Do not 
let the resin dry out.  
3. Once the resin is not compacting any further, the column is filled with 
distilled water. A convex meniscus should form at the very top of the column.  
4. The removable column end piece is screwed back on the column without 
introducing any air bubble into the column. The part with the 25 µm PTFE frit 
is moved on top of the resin leaving 1-2 mm space between resin and frit 
(watch out for liquid that may spill out of the column!).  
5. Once the end piece is in place, the column is connected to the 
chromatography controller. 
6. A flow rate of 10 mL/min (linear velocity ≈ 763 cm/h) is applied to pack the 
column. Water is used for this step. Using 10 mL of slurry, the volume of the 
packed column should be approximately 6 mL under these conditions.  
7. The column is either equilibrated with 10 column volumes (CVs) at a flow 
rate of 2 mL/min (linear velocity ≈ 152 cm/h) with equilibration buffer for 
immediate use, or a 20% ethanol solution for storage at 4-8°C.  
8. The clarified lysate (see 3.4) is loaded with a flow rate of 1 ml/min (linear 
velocity ≈ 76 cm/h).  
9. The resin is then washed with equilibration buffer at a flow rate of 2 mL/min 
(linear velocity ≈ 152 cm/h). Washing is made with at least 5 CVs or until the 
280 nm absorbance reaches baseline value or remains stable.  
10. Bound AAV9 particles are recovered by a one-step elution using 50 mM 
citrate buffer (pH 3) with a flow rate of 2 mL/min. (see Note 18)  
11. Peak fractions are collected with a fraction collector and immediately after 
collection adjusted to a neutral pH by adding 50 µL neutralization buffer per 
mL elute (1M Tris, pH 9). (see Note 19)  
12. The peak fractions are pooled based on the recorded 280 nm absorbance. 
(see Note 20)  
13. At this point continue with Section 3.7 for further sample processing. The 
steps below describe the procedure for column regeneration and storage. 
14. After the elution step, the column is regenerated with 5 M guanidine 
hydrochloride buffer. 
15. The chromatography system and resin can be cleaned using 0.1 M 
phosphoric acid. (see Note 21)  
16. The column is re-equilibrated with equilibration buffer (5 CVs) 
17. For storage at 4-8°C repeat step 7 using 20% Ethanol. 
 
3.7. Ultrafiltration 
With this final step the preparations deriving from the gradient centrifugation 
(3.5) or the immunoaffinity chromatography (see 3.6) can be subjected to 
buffer exchange and concentrated (Figure 1). 
1. Add 12 mL sterile water to the Amicon centrifugal filter unit and centrifuge 
at 3,000xg. 
2. Discard the flow-through. 
3. Add 12 mL sterile DPBS (without calcium and magnesium) to the Amicon 
centrifugal filter units and centrifuge at 3,000xg. (see Note 22)  
4. Discard the flow-through.  
5. Add gradient fraction or the pooled elution fractions to the Amicon Ultra-15 
(a maximum of 12 mL) 
6. Centrifuge at 3,000xg until volume is reduced to 1 mL (the volume depends 
on the desired AAV particle concentration). 
7. Discard the flow-through. 
8. Add DPBS (without calcium and magnesium) to the concentrated particles 
to a final volume of 15 mL. 
9. Repeat steps 6-8 up to 3 times. 
10. Add DPBS to the concentrated particles to a final volume of 15 mL. 
11. Centrifuge at 3,000xg until volume is narrowed down to 500 µL. 
12. The AAV particle suspension can at this point be aliquoted in low retention 
tubes for storage at -80°C. (see Note 23) 
12. For further concentration, transfer the vector suspension to the Amicon 
Ultra-4 and add DPBS to a final volume of 4 mL. 
12. Centrifuge at 3,000xg until the desired volume is reached (the volume 
depends on the desired AAV particle concentration) and discard the flow-
through. 
13. Aliquot the concentrated AAV particle suspension in low retention tubes 
for storage at -80°C (Figure 1).  
 
3.8 Determination of the amount of genome-containing AAV particles 
There is a variety of methods that are frequently used to quantify AAV 
vectors. The most commonly used method is based on qPCR and determines 
the number of vector particles that contain a genome (Figure 1). The 
advantage of this method is that it is fast and inexpensive and it can be 
applied independently of the vector serotype. However, this method does not 
provide any measurement for the infectivity of vectors or the amount of empty 
particles in a preparation. 
 
1. Thaw an aliquot of purified vector at room temperature and pipette twice 
2 µL of the purified vector to low retention reaction tubes. 
2. Dilute 1:104 and 1:105 with PBS using serial dilution steps.  
3. Prepare pDNA standards containing the same template DNA used to 
amplify and quantify the vector genomes. Establish a standard curve based 
on a known number of pDNA copies, ranging from 103 to 107 copies. Note 
that each plasmid copy is equivalent to two single stranded AAV vector 
genomes. 
4. Prepare master mix for PCR by combining 5 µL of 2x Rotor-Gene probe 
PCR master mix, 1 µL forward primer (4 µM), 1 µL reverse primer (4 µM), 1 
µL probe (2 µM). Vortex the master mix before further use. (see Note 25) 
5. Distribute reaction master mix to reaction tubes (8 µL/tube). 
6. Prepare triplicates for each sample. 2 µL of the diluted samples or 
standards are transferred to each of the three tubes containing the reaction 
master mix (10 µL total reaction volume). The tubes are then quickly 
centrifuged for 5-10 sec. 
7. To lyse the AAV capsid and release the vector genome (PCR template) the 
reaction tubes are heated to 95°C for 20 min in the PCR cycler before 
initiating the PCR cycling (40 cycles of 3 sec at 95°C followed by 10 sec at 
60°C).  
8. Determine the number of genome-containing AAV particles, taking into 
account the quantification according to the standard curve, sample dilution, 
and the volume of vector suspension added to the PCR. Of note, a factor 2 
correction has to applied when the single-stranded AAV genome is compared 
to double-stranded plasmid DNA. 
 
Notes	
1. OSRs are available as single-use bioreactor systems up to a scale of 
1,000 L (4). The mixing principle of these reactors is based on 
horizontal movement and shaking of the entire reactor in contrast to the 
mixing of stirred tank bioreactors with an impeller. Key features of the 
OSR technology are high gas transfer rates, low mixing times and low 
specific power consumption (5-7). These characteristics make the OSR 
technology one of the most promising disposable bioreactor platforms 
for animal cell culture for small- and large-scale operations. 
2. The backbone of the shuttle plasmid can be a standard vector 
containing a bacterial origin of replication and a bacterial selection 
gene. The sequence flanked by the ITRs will be incorporated into the 
AAV capsid as the recombinant genome and has to be designed to 
encode the protein or the small RNA of interest. 
3. The pDP helper plasmid is a part of a two-plasmid system typically 
used to produce rAAV vectors. As an alternative, a three-plasmid 
system is commercially available. This system encodes the AAV 
essential genes (rep and cap) and the adenoviral helper genes (VA, 
E2A, E3, and E4) on two separate plasmids. We have compared both 
systems and did not observe a significant impact on the overall vector 
yield between them. 
4. The nature of the Poros™ CaptureSelect™ AAV resins and their 
mechanical resistance to pressures up to 10 MPa allows the 
application of high linear velocities. Hence, these resins are ideally 
suited to process large liquid volumes in a manufacturing scale. 
5. The buffer pH should be around 3 but should be checked using a pH 
probe and be adjusted, if necessary. 
6. The primers are designed according to the recombinant AAV genome 
(pPCR template).  
7. Using the TubeSpin 50 bioreactor a working volume of 20 mL should 
not be exceeded. The ideal working volume is 10-15 mL. Above this, 
the formation of cell clusters can be observed with some cell lines. 
8. When HEK293 cells are seeded in F17 medium at 1×106 cells/mL, cells 
have to be passaged after a maximum of 5 days. Seeding at a lower 
cell density (0.3-0.5×106 cells/mL) allows prolonging the cultivation time 
to 6-7 days. 
9. Based on the growth characteristics of the HEK293 cells the dilution 
factor on the day of transfection is approximately 5 - 6 fold. For a 1-liter 
transfection, a minimum of 200 mL of cell suspension at 1×106 cells/mL 
will need to be seeded three days before the transfection. As the cells 
are typically maintained in 10 mL cultures, it might be necessary, 
depending on the scale of production, to expand the cell culture volume 
already one week (2 passages) before the planned transfection. 
10. The parameters for transient transfection of HEK293 cell suspensions 
are based on protocols optimized in our lab, which are used to define 
total pDNA amount per cell and the w/w ratio of pDNA:PEI (16, 17). In 
combination with the findings from other groups we adapted protocols 
towards the transfection of HEK293 cells in conditioned Freestyle-F17 
medium (8, 9). Depending on several parameters including the cell line, 
the plasmids used for vector production, and the type of AAV, the 
amounts of pDNA and PEI have to be optimized on a case-by-case 
basis. 
11. After a short incubation time (30 sec), an increased turbidity can be 
observed. This is an indicator of complex formation. The tube with 
medium containing pDNA and PEI appears “milky” compared to a tube 
with medium only.  
12. The incubation time depends on the cell line, the medium and the 
process strategy (e.g. batch, fed-batch or perfusion). Under standard 
batch conditions we have observed a maximum accumulation of AAV 
vectors (intracellular) between 48 h and 72 h post-transfection. 
Furthermore, we did not observe any significant increase of the overall 
vector yield for longer process times. After 72 h, the number of 
particles in the culture medium may increase due to a loss of cell 
viability. 
13. Freeze-thaw lysis is mostly used when lysates are directly purified via 
gradient centrifugation. We have observed that detergents in the 
lysate, in particular sodium deoxycholate, can interfere with gradients 
and separation. 
14. The choice of filter depends on the production scale and the particle 
burden of the lysate. At a liter-scale of production, syringe filters are not 
suitable anymore. At this scale, membrane filter capsules connected to 
a peristaltic pump are best suited. With an increasing scale of 
production the usage of membrane filters becomes too expensive and 
inefficient. A solution at this scale is the application of depth filtration to 
remove most of the insoluble particles followed by a membrane 
filtration (0.45 µm-0.8 µm) 
15. The vectors are usually not purified when transfections are carried out 
at a small scale (10-15 mL in TubeSpin 50 bioreactors) for screening 
purposes in order to optimize the transfection efficiency, AAV yields or 
other process parameters. Indeed, depending on the number of 
transfections, this would be very laborious. Also, the quantities 
produced at this scale could not be efficiently recovered. To quantify 
the vector yield, cells are collected and lysed in 1.5 mL tube following 
the same protocol as described in 3.4.1 or 3.4.2. A sample of the 
supernatant (1 mL) is taken as well. The amount of intracellular vector 
and the amount of vector in the cell culture supernatant can be 
quantified using qPCR as described in 3.8. 
16. Triton X-100 addition as compared to the freeze-thaw method is very 
simple to perform and less time consuming. The method is applied 
when lysates are directly purified using immunoaffinity 
chromatography. 
17. The purification of AAV vectors via gradient centrifugation (iodixanol or 
CsCl) has long been used to produce research grade vector 
preparations for pre-clinical studies (18). The combination of gradient 
centrifugation and chromatographic procedures results in a higher 
purity and can help to decreases possible adverse effects of protein 
impurities during in vivo studies. 
18. The elution conditions have been optimized for the step gradient 
elution of AAV9. We found that elution was most efficient at a pH of 3. 
Instead of citrate buffer other acidic buffers can be used for elution.  
19. The AAV capsids are in general relatively heat and pH stable. 
Nevertheless, extended storage under extreme conditions (pH or 
temperature) will result in the denaturation of AAV capsids and a 
decreased vector amount. To avoid this, the pH is immediately 
adjusted to 6.5-7.5 after fraction collection. 
20. The peak is not defined very stringently. One fraction before the A280 
nm signal starts increasing and one fraction after the signal reaches 
baseline are included in the pooled fractions, with the aim to increase 
vector recovery. 
21. It is important to clean the system and resin sufficiently in order to 
avoid residual contaminations. 
22.  Above vector particle concentrations of 1013 vectors/mL, aggregation 
of AAV particles can occur. Previous studies have demonstrated that 
by increasing ionic strength of the suspension buffer, it is possible to 
limit AAV aggregation (19).  
23. The aliquot volume is chosen based on the application and the vector 
amount needed for an experiment. Re-freezing a vial should be 
avoided, as repeated freeze-thaw cycles might cause vector 
degradation. 
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Figure 1: Process-scheme for the transient production of AAV vectors 
with HEK293 cells in suspension. (1.) PEI-mediated transfection of HEK293 
cells in suspension using a 2-plasmid system for AAV expression. (2.a) 
Collection of cells via centrifugation and subsequent cell lysis via repeated 
freeze-thaw cycles. (2.b) Cell lysis by direct addition of Triton X-100 to the cell 
suspension. (3.a) Removal of cell debris (clarification) via centrifugation 
(supernatant contains AAV vectors). (3.b) Clarification by filtration (depending 
on production scale, use membrane and/or depth filtration) (filtrate contains 
AAV vectors). (4.a) Immunoaffinity chromatography purification. (4.b) 
Purification via density gradient centrifugation. (5.) Buffer exchange and 
concentration using ultrafiltration (retentate contains AAV particles). (6.) 
Retentate is aliquoted for storage. The number of genome-containing particles 
in the purified AAV preparation is quantified via qPCR. 
 
 
 
